Search Results - stephen+tomlinson

2 Results Sort By:
Recombinant fusion proteins and complement inhibitors targeting P-selectin, and therapeutic and diagnostic application
Technology: Inventors at MUSC have designed fusion proteins to treat inflammatory and other related pathologies by binding p-selectin (PSel) and modulating complement. Although targeting complement has shown great promise in treating numerous pathologies which has also led to the approval of multiple drugs (e.g. eculizumab, Berinert, Cinryze), targeting...
Published: 2/16/2021   |   Inventor(s): Stephen Tomlinson, Ali Alawieh, Pablo Engel
Keywords(s):  
Category(s): Therapeutic
Delivery of CR2-fH complement inhibitors using gene therapy as novel treatment for age-related macular degeneration (AMD)
Technology: A group of MUSC researchers have developed a novel gene therapy technique to treat age-related macular degeneration (AMD) pathogenesis by introducing a novel complement inhibitory fusion protein (CR2-fH) via an adeno-associated virus (AAV). Data gathered showed that after subretinal delivery of AAV-VMD2-CR2-fH in C57BL/6J mice, the secretion...
Published: 6/21/2019   |   Inventor(s): Monica Vetter, Alejandra Bosco, Baerbel Rohrer, William Hauswirth, Stephen Tomlinson
Keywords(s):  
Category(s): Therapeutic
© 2022. All Rights Reserved. Powered by Inteum